Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2704328 | 0.80 | AR (0.32) | AR | |
| SCHEMBL202164 | 0.72 | AR (0.55) | AR | |
| SCHEMBL13302031 | 0.71 | CFTR (0.37) | CA12CA1CA2CA4CA6 | |
| SCHEMBL2701796 | 0.71 | GAA (0.39) | CA12CA1CA2CA4CA6 | |
| SCHEMBL2703705 | 0.71 | L3MBTL1 (0.39) | AR | |
| SCHEMBL2704454 | 0.71 | AR (0.49) | CA12CA1CA2CA4CA6 | |
| SCHEMBL2704312 | 0.68 | AR (0.35) | CA12CA1CA2CA4CA6 | |
| SCHEMBL9953758 | 0.67 | PTK2 (0.40) | — | |
| SCHEMBL20096576 | 0.64 | CA12 (0.38) | CA12CA1CA2CA4CA6 | |
| SCHEMBL9264759 | 0.64 | GAA (0.55) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088811-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-03 | — | — | US | disclosed |
| US-20100267670-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | ZHANG XUQING | 2010-10-21 | — | — | US | disclosed |
| US-7781473-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMS) | J & J Pharmaceutical Research & Development, LLC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20090131365-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | ZHANG XUQING | 2009-05-21 | — | — | US | disclosed |
| US-7465809-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131365-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | CA12 4544/4885CA1 4793/4885CA2 4683/4885 |
| US-20100267670-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | CA12 4544/4885CA1 4793/4885CA2 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.